Stories about Psilocybin therapy

Subscribe to Psilocybin therapy

23.06.2020 – 09:00

COMPASS Pathways
Mental Health Care Company COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer

London (ots/PRNewswire) - - Piers Morgan appointed earlier in the year as Chief Financial Officer and Gary Gilmour as Director of Preclinical Research COMPASS Pathways, a mental health care company, announced today that it has made a number of new appointments to its leadership team. Trevor Mill joins the company as ...

more
27.04.2020 – 09:00

COMPASS Pathways
Mental Health Care Company COMPASS Pathways Concludes Successful Series B Investment Round

London (ots/PRNewswire) - $80m Raised Will Further the Development of Psilocybin Therapy COMPASS Pathways, a mental health care company, announced today that it has completed a successful $80m Series B investment round. This funding will expand upon COMPASS's lead programme in psilocybin therapy for treatment-resistant depression, supporting research into additional ...

more
13.01.2020 – 11:43

COMPASS Pathways
COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

London (ots/PRNewswire) - COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use of COMPASS's ...

more
12.12.2019 – 09:00

COMPASS Pathways
COMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers

London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...

more
23.10.2018 – 15:24

COMPASS Pathways
COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression

London (ots/PRNewswire) - COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for treatment-resistant depression. ...

more
22.08.2018 – 15:29

COMPASS Pathways
COMPASS Pathways Receives FDA Approval for Psilocybin Therapy Clinical Trial for Treatment-resistant Depression

London (ots/PRNewswire) - COMPASS Pathways, a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression. Regulatory ...

more

1